HIV genotyping provides susceptibility information for integrase inhibitors (INI). Intended for patients with viral load >500 copies/mL.
Reverse Transcription Polymerase Chain Reaction/Sequencing
Lavender (EDTA), pink (K2EDTA), or plasma preparation tube.
Separate plasma from cells within 6 hours. Transfer 4 mL plasma to an ARUP Standard Transport Tube. (Min: 1.5 mL)
Serum. Heparinized specimens.
Please submit most recent viral load and test date, if available.
On cells: Ambient: 6 hours; After separation from cells: Ambient: 24 hours; Refrigerated: 5 days; Frozen: 4 months
The entire integrase-encoding region is sequenced. Mutations associated with resistance to integrase inhibitors are reported. Mutations in viral sub-populations below 20 percent of total may not be detected.
Compliance Statement D: For laboratory tests using a manufactured RUO kit. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
This test may be unsuccessful if the plasma HIV-1 RNA viral load is less than 500 HIV-1 RNA copies per mL of plasma.
|Component Test Code*||Component Chart Name||LOINC|
|2004458||HIV-1 Integrase Inhib. Resistance, Seq||72560-6|
- HIV Drug Resistance
- HIV Integrase Genotype
- HIV Integrase Inhibitor Resistance
- HIV Treatment Susceptibility Testing
- HIV1 Integrase Resistance
- HIV1 Integrase Sequencing
- HIV1 Sequencing
- Raltegravir (Isentress(TM)) Resistance